CASC3 and neoplasm: Therefore, the biocomposite developed in current study combines several advantages, including the synergistic antitumor effect of DR5-selective variant DR5-B with BTZ [61], sustained BTZ release, as well as enhanced internalization of AmphPVP-BTZ-DR5-B-iRGD biocomposites due to the modification with tumor-penetrating fusion protein DR5-B-iRGD.